• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 5. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Sulfanilides

Recent Advances in the Study of N-(5-Bromo-2-methoxyphenyl)ethane-1-sulfonamide (CAS: 1247613-58-6)

N-(5-Bromo-2-methoxyphenyl)ethane-1-sulfonamide (CAS: 1247613-58-6) has recently emerged as a compound of significant interest in the field of chemical biology and medicinal chemistry. This sulfonamide derivative has shown promising potential in various therapeutic applications, particularly in the modulation of specific biological pathways. Recent studies have focused on its synthesis, pharmacological properties, and mechanism of action, providing valuable insights for future drug development.

The compound's structural features, including the bromo and methoxy substituents, contribute to its unique reactivity and binding affinity. Researchers have employed advanced spectroscopic techniques, such as NMR and mass spectrometry, to characterize its molecular structure and confirm its purity. Additionally, computational modeling studies have been conducted to predict its interactions with biological targets, further elucidating its potential as a therapeutic agent.

In vitro and in vivo studies have demonstrated that N-(5-Bromo-2-methoxyphenyl)ethane-1-sulfonamide exhibits notable activity against specific enzyme targets, including those involved in inflammatory and oncogenic pathways. For instance, recent findings indicate its inhibitory effects on cyclooxygenase-2 (COX-2) and certain kinases, suggesting its applicability in anti-inflammatory and anticancer therapies. These results are supported by robust experimental data, including IC50 values and kinetic studies.

One of the key challenges in the development of this compound lies in optimizing its pharmacokinetic properties, such as bioavailability and metabolic stability. Recent efforts have focused on structural modifications to enhance its drug-like characteristics while retaining its biological activity. These modifications have been guided by structure-activity relationship (SAR) studies, which have identified critical functional groups responsible for its efficacy.

The safety profile of N-(5-Bromo-2-methoxyphenyl)ethane-1-sulfonamide has also been a subject of investigation. Preliminary toxicology studies have shown that the compound is well-tolerated in animal models at therapeutic doses, with no significant adverse effects reported. However, further studies are required to assess its long-term safety and potential off-target effects.

In conclusion, N-(5-Bromo-2-methoxyphenyl)ethane-1-sulfonamide represents a promising candidate for further development in medicinal chemistry. Its unique structural and pharmacological properties make it a valuable tool for understanding biological mechanisms and a potential lead compound for drug discovery. Future research should focus on advancing its preclinical development and exploring its therapeutic applications in greater detail.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)